24 / 34
median
PS
•
The subset of patients available for this RNA signature, (n=439, with only n=363 overlapping with the subset with
available DNA data) is not representative any more of the ITT in terms of treatment effects:
•
HR in the population with RNA samples available is 0.92 (95%CI: 0.74 – 1.16) vs
HR=0.82 (95%CI: 0.71 -0.93) in the ITT population
Pending: RNA Exploratory Validation
Tejpar, World GI 2017
CMS and other gene expression signatures pending